BARCELONA, May 19, 2011 /PRNewswire/ -- Iroko Cardio International (Geneva, Switzerland),a privately held pharmaceutical company dedicated to reducing the incidence of major adverse cardiac events (MACE), has adopted Veeva CRM to support all of its representatives in nine European countries. Both field and office-based users have begun to
"I've lived through several CRM implementations before, and the 'sell' to end users was never easy," confided Juergen Guenther, vice president of customer operations at Iroko. "I'm pleased to say that the feedback on Veeva's system has been very positive. Users appreciate the well-designed interface, the features we've added to the standard version, and the quick screen refresh times."
Veeva's Professional Services team worked closely with Iroko Cardio to deploy the Veeva CRM system to all users in only six weeks. Time to market was a major advantage over traditional client/server CRM systems, which typically require a minimum of three to six months to deploy.
"As a small, but pan-European company, we weren't able to embark on a lengthy requirements definition, configuration, and implementation exercise," explained Guenther. "With Veeva, we were spared that; we experienced a very fast, user-oriented design phase for changes to the basic system, often with immediate response on design requests. And by relying on the Veeva Professional Services team to help us load data and create reports for the first three months of operation, we had an extraordinarily easy transition."
Veeva Systems has rapidly become the leading provider of Pharma CRM solutions globally. As a multi-tenant SaaS application built in the cloud, Veeva CRM requires no hardware or software to purchase, scale, or maintain. In addition, all Veeva customers benefit from free, automatic upgrades so users are always on the most up-to-date version of the software and benefit from the very latest compliance changes and system enhancements. Changes can be made to the system instantly, without user retraining or additional third-party costs.
"By designing Veeva CRM to fit the specific requirements of the European pharmaceutical industry, we have enabled companies like Iroko Cardio to deploy quickly and painlessly," said Dan Goldsmith, general manager, Veeva Europe. "And our truly multi-tenant technology platform anchors a solution that our customers will never outgrow."
"The fact that Veeva's solution is cloud-based and therefore easy on our IT infrastructure was very compelling," added Guenther. "Plus, we can add promising new features later on, without undergoing massive development projects."
About Iroko Cardio
Iroko Cardio is a privately held pharmaceutical company located in Geneva, Switzerland, and Philadelphia, USA. In close collaboration with regional distribution partners, Iroko produces and promotes Aggrastat/Agrastat(R) worldwide with the exception of the USA. Iroko Cardio aims to contribute to the reduction of Major Adverse Cardiac Events in the regions it serves.
About Veeva Systems
Veeva Systems is the leader in cloud-based solutions for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has over 80 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Founded in 2007, Veeva is a privately-held company headquartered in the San Francisco Bay Area, with offices in Philadelphia, Barcelona, Beijing, Shanghai, and Tokyo. For more information, visit http://www.veevasystems.com.
Copyright (c) 2011 Veeva Systems. All rights reserved. Veeva and the Veeva logo are registered trademarks of Veeva Systems. Veeva Systems owns other registered and unregistered trademarks. Other names used herein may be trademarks of their respective owners.
Media Contact Selma Nawaz European Marketing Director Veeva Systems email@example.com
SOURCE Veeva Systems
Subscribe to our Free Newsletters!
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All